Novartis Inks $5.3B Deal To Get Eye Drug From Takeda
Novartis said Thursday it is going to pay up to $5.3 billion to buy a dry-eye drug from Takeda, a deal the Switzerland-based company said would allow it to boost its...To view the full article, register now.
Already a subscriber? Click here to view full article